You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 16, 2024

Details for Patent: 9,255,087

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,255,087 protect, and when does it expire?

Patent 9,255,087 protects ROZLYTREK and is included in one NDA.

This patent has thirty-six patent family members in twenty-seven countries.

Summary for Patent: 9,255,087

Title:	Substituted indazole derivatives active as kinase inhibitors
Abstract:	Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.
Inventor(s):	Lombardi Borgia; Andrea (Paullo, IT), Menichincheri; Maria (Milan, IT), Orsini; Paolo (Legnano, IT), Panzeri; Achille (Merate, IT), Perrone; Ettore (Boffalora Sopra Ticino, IT), Vanotti; Ermes (Milan, IT), Nesi; Marcella (Saronno, IT), Marchionni; Chiara (Milan, IT)
Assignee:	NERVIANO MEDICAL SCIENCES S.R.L. (Nerviano (MI), IT)
Application Number:	14/534,617
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,255,087

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Genentech Inc	ROZLYTREK	entrectinib	CAPSULE;ORAL	212725-001	Aug 15, 2019		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION	⤷ Try a Trial
Genentech Inc	ROZLYTREK	entrectinib	CAPSULE;ORAL	212725-001	Aug 15, 2019		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER	⤷ Try a Trial
Genentech Inc	ROZLYTREK	entrectinib	CAPSULE;ORAL	212725-002	Aug 15, 2019		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION	⤷ Try a Trial
Genentech Inc	ROZLYTREK	entrectinib	CAPSULE;ORAL	212725-002	Aug 15, 2019		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 9,255,087

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	07112881	Jul 20, 2007

International Family Members for US Patent 9,255,087

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	067599	⤷ Try a Trial
Australia	2008280283	⤷ Try a Trial
Brazil	PI0814628	⤷ Try a Trial
Canada	2693901	⤷ Try a Trial
Chile	2008002129	⤷ Try a Trial
China	101754956	⤷ Try a Trial
China	103923072	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.